Our people

Here for Good: The human element inspiring our cancer research

Learn how one doctor turned his family connection to cancer into a career driven by scientific innovation

May 27, 2022

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Dr. Greg Lubiniecki

Advances in oncology research require a firm commitment to scientific investigation. Behind every innovation, there are countless researchers, doctors and clinicians who dedicate their lives to helping patients through scientific breakthroughs.  

At Merck, Dr. Gregory Lubiniecki, vice president, oncology clinical research, is a senior leader who oversees cancer research. He’s also a practicing clinician, continuing to see patients — adding a human connection to his research.  

For Lubiniecki, having a “one-on-one connection” with patients is important both personally and professionally, and helps to keep the patient experience at the forefront when designing clinical studies.   

Dr. Lubiniecki’s drive to pursue a career in oncology was motivated by his family’s experience with cancer — watching his mother go through surgery and chemotherapy while he was in high school — and his own scientific curiosity. “The complexity of the molecular biology involved in cancer was very intriguing to me,” he said.

Dr. Lubiniecki and his team play a critical role in advancing Merck’s effort to help save and improve lives around the world through leading-edge science. With an ongoing connection to patients and his research firmly focused on the future, Dr. Lubiniecki is excited about where cancer care may go next.  

“I’m very excited about several clinical projects that are going to try and improve the lives of patients who are fighting cancer.”

  • Dr. Gregory Lubiniecki

Watch the video to learn more about Dr. Lubiniecki

here for good graphic
Our people

How Wilson, N.C., plays a critical role in our commitment to supply

Meet the North Carolina-based manufacturing team that’s producing and packaging our investigational oral antiviral COVID-19 medicine

March 2, 2022

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

a worker in our Wilson NC facility

From the earliest stages of the COVID-19 pandemic, we knew we had a responsibility to rise to the challenge of this unique moment. That’s why our teams mobilized like never before to ensure we were ready to address a global need.

In late 2020, our manufacturing teams began utilizing our global supply network — including sites in nine countries across three continents — to start production of our investigational oral antiviral COVID-19 medicine. This monumental effort made it possible for us to produce 10 million courses of therapy in 2021, with at least another 20 million on track for 2022.

A major part of that effort takes place in Wilson, North Carolina, where our colleagues are working tirelessly to carry out our mission and ensure supply during this crucial time.

“This is a perfect example of the company coming together as one team with a single goal,” said Francisco Toste, associate vice president, plant management at the Wilson site. “I am proud to work for our great company because of the impact that we make for patients around the world in helping them combat serious disease.”

Meet the team in Wilson behind this heroic effort:

aerial view of the Wilson NC facility